Tizanidine Tablet
Product Images NDC 0615-8468

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 0615-8468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Tizanidine Tabs 8468 8469 1)

Chemical structure diagram of tizanidine hydrochloride, showing the arrangement of atoms including chlorine, nitrogen, sulfur, and hydrogen in the molecular framework.*

FDA Label Image

Figure (Tizanidine Tabs 8468 8469 2)

A line graph showing plasma tizanidine concentration (ng/mL) over 24 hours post-dosing, comparing four groups: 2 x 4 mg tizanidine tablets with food, tablets without food, capsules with food, and capsules without food. Concentrations peak around 1-2 hours after dosing, then decline gradually to near zero by 24 hours.*

FDA Label Image

Figure (Tizanidine Tabs 8468 8469 3)

A line graph showing improvement in Ashworth Score over hours post-dose for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement in Ashworth Score, and the x-axis shows hours post-dose from 0 to 6. Data points include error bars for variability.*

FDA Label Image

Figure (Tizanidine Tabs 8468 8469 4)

A line plot showing improvement in Ashworth Score over time comparing tizanidine (mean dose 28.8 mg) and placebo. Time points include End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). Tizanidine shows greater score improvement than placebo at all time points with error bars indicating variability.*

FDA Label Image

Principal Display Panel (Tizanidine Tabs 8468 8469 5)

Label for Tizanidine Tablets USP 2 mg by NCS HealthCare of KY, LLC dba Vangard Labs. The label displays barcodes, lot number 8468, and space for expiration date and receipt information. It includes storage instructions and a note that tablets contain 2.29 mg tizanidine HCl equivalent to 2 mg base, with a quantity of 30 tablets per package. Packaging is marked for institutional use only, manufactured by Cadila for Viona.*

FDA Label Image

Principal Display Panel (Tizanidine Tabs 8468 8469 6)

Label for Tizanidine Tablets USP 4 mg, a prescription oral tablet manufactured by Cadila for Viona and packaged by Vangard Labs in Glasgow, KY. The label includes lot number 8469, barcode, quantity of 30 tablets, storage instructions, and a note that the tablets are not interchangeable with capsules. It also specifies each tablet contains 4.58 mg tizanidine HCl, USP equivalent to 4 mg tizanidine base, for institutional use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.